Beximco Pharmaceuticals 미래 성장

Future 기준 확인 3/6

Beximco Pharmaceuticals (는) 각각 연간 16.5% 및 12.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.6% 로 예상됩니다.

주요 정보

16.5%

수익 성장률

16.5%

EPS 성장률

Pharmaceuticals 수익 성장	19.6%
매출 성장률	12.8%
향후 자기자본 수익률	14.6%
애널리스트 커버리지	Low
마지막 업데이트	13 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

AIM:BXP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (BDT Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2027	64,408	9,473	6,491	9,846	1
6/30/2026	56,909	8,056	5,576	8,633	1
6/30/2025	50,280	6,732	4,789	7,545	1
9/30/2024	44,946	5,957	5,391	7,353	N/A
6/30/2024	44,392	5,830	6,130	8,364	N/A
3/31/2024	43,085	5,330	5,962	8,373	N/A
12/31/2023	41,652	4,916	5,696	8,176	N/A
9/30/2023	40,639	4,720	5,486	8,109	N/A
6/30/2023	39,267	4,614	3,442	6,085	N/A
3/31/2023	37,974	4,477	2,650	5,562	N/A
12/31/2022	37,379	4,629	1,323	3,922	N/A
9/30/2022	35,987	5,105	1,161	3,910	N/A
6/30/2022	34,669	5,123	2,275	5,214	N/A
3/31/2022	33,660	5,738	3,143	5,950	N/A
12/31/2021	32,062	6,097	4,153	7,502	N/A
9/30/2021	31,037	5,519	3,983	6,796	N/A
6/30/2021	29,494	5,128	3,465	6,023	N/A
3/31/2021	28,269	4,578	3,667	5,592	N/A
12/31/2020	27,517	4,017	2,198	4,025	N/A
9/30/2020	26,235	3,724	2,354	4,895	N/A
6/30/2020	25,612	3,515	3,267	5,542	N/A
3/31/2020	25,056	3,405	-187	4,319	N/A
12/31/2019	24,202	3,251	834	5,814	N/A
9/30/2019	23,735	3,143	-114	4,397	N/A
6/30/2019	22,817	3,033	-1,585	2,960	N/A
3/31/2019	21,724	2,852	-300	2,893	N/A
12/31/2018	20,188	2,708	-2,393	1,397	N/A
9/30/2018	18,823	2,647	-3,106	1,611	N/A
6/30/2018	17,717	2,537	N/A	1,819	N/A
3/31/2018	16,924	2,513	N/A	2,416	N/A
12/31/2017	16,517	2,431	N/A	2,873	N/A
9/30/2017	16,022	2,356	N/A	2,643	N/A
6/30/2017	15,509	2,227	N/A	2,634	N/A
3/31/2017	14,687	2,224	N/A	2,042	N/A
12/31/2016	14,271	2,133	N/A	1,883	N/A
9/30/2016	13,736	2,060	N/A	1,932	N/A
6/30/2016	13,356	1,965	N/A	2,113	N/A
12/31/2015	12,966	1,954	N/A	1,835	N/A
9/30/2015	12,573	1,804	N/A	2,095	N/A
6/30/2015	12,134	1,813	N/A	1,937	N/A
3/31/2015	11,628	1,605	N/A	2,510	N/A
12/31/2014	11,207	1,528	N/A	2,216	N/A
9/30/2014	11,139	1,476	N/A	2,459	N/A
6/30/2014	10,847	1,471	N/A	2,146	N/A
3/31/2014	10,804	1,452	N/A	2,196	N/A
12/31/2013	10,491	1,405	N/A	2,130	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BXP 의 연간 예상 수익 증가율( 16.5% )이 saving rate( 2.1% 보다 높습니다. ).

수익 vs 시장: BXP 의 연간 수익( 16.5% ) UK 시장( 14.6% 보다 빠르게 성장할 것으로 예상됩니다. 14.6% 연간).

고성장 수익: BXP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: BXP 의 수익(연간 12.8% ) UK 시장( 3.5% 보다 빠르게 성장할 것으로 예상됩니다. 3.5% 연간).

고성장 수익: BXP 의 수익(연간 12.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BXP 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 14.6 %).

Beximco Pharmaceuticals 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Beximco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024

Beximco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024

Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024

Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Beximco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 19, 2023

Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022

Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended 30 June 2022

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

Beximco Pharmaceuticals Limited Updates on the Supply of Covid-19 Vaccine

Beximco Pharmaceuticals Limited Announces Board Changes

Beximco Pharmaceuticals Limited Provides Update on the Supply of COVID-19 Vaccine

Beximco Pharmaceuticals Limited Confirms Quamrun Naher Ahmed and Reem H. Shamsuddoha as Non-Executive Directors

Beximco Pharmaceuticals Limited Announces Directors Appointments

Beximco Pharmaceuticals Limited Enters into A Memorandum of Understanding for the Supply and Distribution of 30 Million Doses of the Oxford University/AstraZeneca SARS-CoV-2 Vaccine, AZD1222, in Bangladesh

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration (Fda) Approval for Antiarryhtmic Drug Flecainide

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견